Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Volunteers
Health Professionals

What is the purpose of this trial?

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ajay Venkatakrishnan

ajay.venkatakrishnan@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Study Locations

Smilow Cancer Hospital at Enfield
Smilow Cancer Hospital at Glastonbury (CT131)
Smilow Cancer Hospital at Greenwich (CT112)
Smilow Cancer Hospital at Saint Francis (CT008)
Smilow Cancer Hospital Care Center - Derby (CT114)
Smilow Cancer Hospital Care Center - Fairfield (CT127)
Smilow Cancer Hospital Care Center - Guilford (CT078)
Smilow Cancer Hospital Care Center - Hamden (CT077)
Smilow Cancer Hospital Care Center - Long Ridge (CT134)
Smilow Cancer Hospital Care Center - North Haven (CT125)

Principal Investigator

Kiran Turaga, MD, MPH
Professor of Surgery (Oncology); Division Chief, Surgical Oncology, Surgery; Assistant Medical Director, Clinical Trials Office

Sub-Investigators

Last Updated
08/18/2026
Study IRB
#2000038216